FCCPC Commits to Prevent Importation of Substandard Cough Syrup
Please share this story:
The Federal Competition and Consumer Protection Commission says it will work with relevant authorities to prevent the entry or sale of substandard cough syrups in the country's market.
A statement released on Thursday by Mr. Babatunde Irukera, Executive Vice President of FCCPC Abuja, advised stakeholders to strictly adhere to NAFDAC protocols identified in the agency's regulations and guidelines.
>Irukera said the National Agency for Food and Drug Administration and Control has issued a warning to importers, distributors, retailers and consumers to refrain from importing, distributing, sell and use four cough syrups.
He said the cough syrups were made by Maiden Pharmaceuticals and made in India.
According to him, the products include Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup.
"In further reinforcing and propagating the NAFDAC Alert and Warning, the FCCPC hereby and now issues this Advisory.
"In particular, advise any relevant stakeholder to strictly adhere to the NAFDAC protocols identified in the NAFDAC publication or regulations and guidelines.
"NAFDAC's warning is consistent with a global medical product alert issued by the World Health Organization on October 5, which linked the deaths of sixty-six children in The Gambia to said cough syrups .
"Reports indicate that the drugs were exclusively delivered to The Gambia.
"The existence of informal and uncontrolled markets, mutual policies of regional trade liberalization, including under Treaty obligations, make it conceivable, and certainly not unlikely, that exposure to Nigeria could occur", he said.
Irukera urged citizens who preferred to contact the Commission on this matter to forward them to [email protected] for onward transmission to NAFDAC.
The News Agency of Nigeria recalls that NAFDAC on October 11 sounded the alarm over the use of four cough syrups linked to acute kidney injury and death of children in The Gambia.
NA
Please share this story:
The Federal Competition and Consumer Protection Commission says it will work with relevant authorities to prevent the entry or sale of substandard cough syrups in the country's market.
A statement released on Thursday by Mr. Babatunde Irukera, Executive Vice President of FCCPC Abuja, advised stakeholders to strictly adhere to NAFDAC protocols identified in the agency's regulations and guidelines.
>Irukera said the National Agency for Food and Drug Administration and Control has issued a warning to importers, distributors, retailers and consumers to refrain from importing, distributing, sell and use four cough syrups.
He said the cough syrups were made by Maiden Pharmaceuticals and made in India.
According to him, the products include Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup.
"In further reinforcing and propagating the NAFDAC Alert and Warning, the FCCPC hereby and now issues this Advisory.
"In particular, advise any relevant stakeholder to strictly adhere to the NAFDAC protocols identified in the NAFDAC publication or regulations and guidelines.
"NAFDAC's warning is consistent with a global medical product alert issued by the World Health Organization on October 5, which linked the deaths of sixty-six children in The Gambia to said cough syrups .
"Reports indicate that the drugs were exclusively delivered to The Gambia.
"The existence of informal and uncontrolled markets, mutual policies of regional trade liberalization, including under Treaty obligations, make it conceivable, and certainly not unlikely, that exposure to Nigeria could occur", he said.
Irukera urged citizens who preferred to contact the Commission on this matter to forward them to [email protected] for onward transmission to NAFDAC.
The News Agency of Nigeria recalls that NAFDAC on October 11 sounded the alarm over the use of four cough syrups linked to acute kidney injury and death of children in The Gambia.
NA
What's Your Reaction?
